Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

House Dust Mite SLIT in Elderly Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Andrzej Bozek, Medical University of Silesia
ClinicalTrials.gov Identifier:
NCT01605760
First received: May 17, 2012
Last updated: May 21, 2012
Last verified: May 2012
  Purpose

The safety and efficacy of specific sublingual immunotherapy for house dust mite allergens in patients over 60 years of age with allergic rhinitis and a confirmed allergy to house dust mites were the focus of the stu First, 111 patients, ages 60-75 years, with allergic rhinitis and with a confirmed allergy to D. pteronyssinus and D. farinae by the use of skin prick tests, serum-specific IgE and nasal provocation tests were included. Patients were individually randomised to groups: active or placebo using a double-blind method. A total of 51 subjects in the sublingual allergen-specific immunotherapy (SLIT) group (Staloral 300R, Stallergens, France) and 57 in the placebo group were monitored for three years. The patients had to record on a diary card whenever they used anti-allergic medications.


Condition Intervention Phase
Allergic Rhinitis
Drug: immunotherapy Staloral
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: House Dust Mite Sublingual Immunotherapy: a Double-blind, Placebo Control Study in Elderly Patients.

Further study details as provided by Medical University of Silesia:

Primary Outcome Measures:
  • Number of participants with adverse event during immunotherapy [ Time Frame: three year ] [ Designated as safety issue: Yes ]
    Safety assessment of sublingual immunotherapy on the basis of the monitoring clinical adverse events during treatment by the use of a patient diary and medical examination.


Secondary Outcome Measures:
  • Change from baseline of nasal symptoms after immunotherapy [ Time Frame: three year ] [ Designated as safety issue: No ]
    Assessment of reducing the need for symptom-targeted drugs, primarily antihistamines and reducing of nasal symptoms during treatment in study patients (diary monitoring).


Enrollment: 111
Study Start Date: January 2008
Study Completion Date: March 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: non immunotherapy treatment Drug: immunotherapy Staloral
Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
Active Comparator: sublingual immunotherapy course Drug: immunotherapy Staloral
Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).

  Eligibility

Ages Eligible for Study:   60 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with allergic rhinitis who fulfilled the ARIA criterion and had a positive skin prick test (SPT), were positive for specific immunoglobulin E (sIgE) and had positive nasal provocation tests (NPTs) by Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f) were included in the study

Exclusion Criteria:

  • Patients with any of the following characteristics were excluded:

    • hypersensitivity to other allergens,
    • non-allergic rhinitis (especially senile or vasomotor rhinitis) or
    • severe non-stable diseases (especially bronchial asthma). However, stable coronary disease, diabetes, arterial hypertension and well-controlled, mild or atopic bronchial asthma were permitted.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01605760

Locations
Poland
Allergology Outpatient Clinic
Zabrze, Poland, 41-800
Sponsors and Collaborators
Medical University of Silesia
  More Information

No publications provided

Responsible Party: Andrzej Bozek, Medical Doctor, Medical University of Silesia
ClinicalTrials.gov Identifier: NCT01605760     History of Changes
Other Study ID Numbers: 657898/2008
Study First Received: May 17, 2012
Last Updated: May 21, 2012
Health Authority: Poland: Ethics Committee

Keywords provided by Medical University of Silesia:
immunotherapy
elderly

ClinicalTrials.gov processed this record on November 25, 2014